阿那曲唑和他莫昔芬对绝经后激素受体阳性转移性乳腺癌患者的疗效及肿瘤相关炎性因子的影响对比

摘要

目的 比较阿那曲唑和他莫昔芬对绝经后激素受体阳性转移性乳腺癌[HR(+)MBC]患者的疗效及血清肿瘤相关炎性因子表达水平的影响.方法 选取50例HR(+)MBC患者,其中使用芳香化酶抑制剂阿那曲唑治疗者26例(阿那曲唑组),使用传统药物他莫昔芬治疗者24例(他莫昔芬组),比较患者的治疗效果以及治疗前后血清白细胞介素(IL)-1、IL-2、IL-6、IL-8、IL-10和肿瘤坏死因子-α(TNF-α)的表达水平.结果 阿那曲唑组的临床疗效优于他莫昔芬组(P<0.05).治疗后,他莫昔芬组IL-1、IL-8、IL-10和TNF-α水平较治疗前下降(均P<0.05),阿那曲唑组IL-1、IL-8、IL-10、TNF-α水平较治疗前降低(均P<0.05),阿那曲唑组IL-1、IL-2、IL-6、IL-8、IL-10、TNF-α水平均低于他莫昔芬组(均P<0.05).结论 阿那曲唑对HR(+)MBC的疗效优于他莫昔芬;两种药物对肿瘤生长相关炎性因子表达水平的影响存在差异,而这种差异可能与疗效密切相关.%Objective To Compare the effects of anadrazole and tamoxifen on the efficacy and expression levels of serum tumor-associated inflammatory factors in patients with hormone receptor-positive metastatic breast cancer[ HR( +) MBC] after menopause. Methods Of 50 patients with HR( +)MBC involved,26 patients(anadrazole group) were administered aromatase inhibitor,anadrazole,and 24 patients ( tamoxifen group) were administered traditional medicine,tamoxifen. The therapeutic efficacy and the expression levels of serum interleukin (IL)-1,IL-2,IL-6,IL-8,IL-10 and tumor necrosis factor-α(TNF-α) before and after treatment were compared between the two groups. Results The clinical efficacy of the anastrozole group was significantly superior to that of the tamoxifen group(P<0. 05). After treatment, the levels of IL-1,IL-8,IL-10 and TNF-αdecreased in the tamoxifen group compared to the levels before treatment(all P<0. 05),the levels of IL-1,IL-8,IL-10 and TNF-αdecreased in the anadrazole group compared to the levels before treatment(all P<0. 05),and the levels of IL-1,IL-2,IL-6,IL-8,IL-10 and TNF-αwere lower in the anadrazole group than those in the tamoxifen group(all P<0. 05). Conclusion The efficacy of anastrozole is superior to that of tamoxifen for HR( +) MBC. There is a difference in the effect on the expression levels of tumor-associated inflammatory factors between the two medicines,and that difference might be related to the efficacy closely.